Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery (KID PRO AM)

This study has been completed.
Information provided by (Responsible Party):
David Axelrod, Stanford University Identifier:
First received: November 19, 2010
Last updated: May 28, 2014
Last verified: May 2014

Children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). Approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after the procedure. We currently have few medications to prevent this kidney injury. The hypothesis of this study is that giving aminophylline after heart surgery can decrease the acute kidney injury.

Condition Intervention
Acute Kidney Injury
Drug: Aminophylline
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Placebo Controlled Trial of Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery With Cardiopulmonary Bypass

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Acute Kidney Injury measured by pRIFLE (pediatric "Risk, Injury, Failure, Loss, End Stage" criteria [ Time Frame: 5 days ] [ Designated as safety issue: No ]
    pRIFLE is a measure of acute kidney injury.

Estimated Enrollment: 160
Study Start Date: November 2010
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Aminophylline
Patients to receive aminophylline 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
Drug: Aminophylline
5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
Placebo Comparator: Placebo
Normal Saline Placebo
Drug: Placebo
Normal Saline

Detailed Description:

Patients are randomized to receive aminophylline or placebo for 72 hours, in a blinded fashion. Serum theophylline levels monitor for safety of aminophylline dose. Goal theophylline levels is 5-7 mcg/ml. Laboratory results will be faxed directly to the pharmacy who will adjust subsequent aminophylline dosing to maintain appropriate theophylline levels. Urine output and serum creatinine levels will be monitored to assess acute kidney injury. Serum Neutrophil Gelatinase Associated Lipocalin (NGAL) levels will also be monitored.


Ages Eligible for Study:   36 Weeks to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Less than 18 years old, undergoing cardiac surgery with bypass

Exclusion Criteria:

  • History of arrythmia or seizure, on ECMO, already taking aminophylline/theophylline, liver failure, sepsis, on renal replacement therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01245595

United States, California
Lucile Packard Childrens' Hospital
Palo Alto, California, United States, 94304
Sponsors and Collaborators
Stanford University
  More Information

No publications provided

Responsible Party: David Axelrod, MD, Clinical Assistant Professor, Stanford University Identifier: NCT01245595     History of Changes
Other Study ID Numbers: 18977
Study First Received: November 19, 2010
Last Updated: May 28, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Stanford University:
Acute Kidney Injury
Cardiopulmonary bypass

Additional relevant MeSH terms:
Acute Kidney Injury
Kidney Diseases
Renal Insufficiency
Urologic Diseases
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cardiotonic Agents
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Protective Agents
Purinergic Agents
Purinergic Antagonists
Purinergic P1 Receptor Antagonists
Respiratory System Agents
Therapeutic Uses processed this record on November 19, 2014